Techstep Q2 2026 slides: revenue rises but margins compress sharply

Techstep’s Q2 2026 showed revenue growth of 12% to NOK 228.8m, but profitability deteriorated sharply: net gross profit fell 25% to NOK 52m and gross margin contracted 11pp to 22.7%. Adjusted EBITA turned negative at NOK -12.9m (vs +NOK 0.4m prior year) and the company reported a net loss of NOK 30.5m, alongside operating cash flow after investments of NOK -16.1m. Liquidity stress (cash of NOK 4.6m at quarter-end) prompted a bridge facility of NOK 40m and a rights issue of at least NOK 83.3m at NOK 1/share, while management launched a restructuring plan targeting NOK 218m annualized cost base (15% reduction) and headcount cut from 260 to ~160 FTE by Q4 2026. Shares near 52-week lows reflect investor caution ahead of the equity raise and turnaround execution.

Analysis

This is less a revenue-growth story than a capital-structure reset. The immediate winner is whoever owns the underwriting risk; the equity is being repriced as an option on survival rather than a normal operating business, so the key question over the next 4-8 weeks is not upside growth but whether the raise clears without further concessions. If the company can execute the rights issue and pay down the bridge, the balance-sheet overhang should ease, but that does not fix the mix problem: hardware-heavy sales and weaker recurring software still imply structurally lower gross margin and lower valuation multiples.

The real second-order loser is the company’s own competitive positioning. A cost-out can protect EBITDA in the next 2-3 quarters, but if software ARR keeps leaking and device mix stays high, Techstep risks becoming a lower-quality reseller with less customer lock-in; that usually leads to weaker pricing, more working-capital strain, and higher churn when larger peers bundle the same services. The balance-sheet cleanup could also prompt vendor and customer caution until the restructuring proves it will not disrupt service levels, especially in health and public-sector rollouts where delays translate into lost implementation slots, not just deferred revenue.

The contrarian point is that the market may be focusing too much on dilution and too little on the implied floor after the raise. Once the financing is done, the stock may stabilize if cash burn is cut and the bridge is repaid; that is a short-term technical setup, not a fundamental re-rating. What would falsify any stabilization thesis is continued decline in own-software ARR, a worse-than-expected Q3 goodwill write-down, or evidence that the cost reduction damages delivery capacity faster than it lowers expenses.

Key Decisions for Investors

• No immediate long in the equity through the rights-issue window: the risk/reward is dominated by dilution and execution risk over the next 4-10 weeks, not operating upside.
• Watch for a post-rights-issue tactical rebound only if the stock holds above the issue price after settlement and Q3 ARR stops declining; otherwise treat any bounce as sellable.
• Use the Q3 update as the key catalyst alert: if own-software revenue or ARR is still down year-over-year, the turnaround thesis is broken and the shares deserve a lower multiple for 6-18 months.
• If you have exposure to Nordic small-cap software/IT-services, rotate toward better-capitalized recurring-revenue names and avoid balance-sheet-dependent turnaround stories until financing is complete.
• Set a risk alert for further impairment or covenant stress: a larger-than-expected goodwill write-down or additional financing need would likely trigger another leg lower and should be treated as a hard falsifier.